eGFR slope

There are 14 papers on eGFR slope in aging research: 2 trials and 8 observational studies in people, 4 reviews. The newest story, Nov 9, 2026: “DNA aging patterns differ across type 2 diabetes groups”.

Biomarker

14 papers study it38 more mention it16 findings

10 new papers in 30 daysSee all 52 papers on eGFR slope

“Higher GMI and HbA1c were associated with faster eGFR decline”
Association of continuous glucose monitoring metrics with cardiovascular and kidney outcomes in type 2 diabetes: Data from the GRADE-CGM substudyJournal of diabetes and its complications2026doi:10.1016/j.jdiacomp.2026.109439
  • Human trial2
  • Humans8

Interventions

3

SGLT2 inhibitors

upin humans2downin humans1no changein humans1

4 studies
  1. SGLT2 inhibitors improve eGFR slope in humans (type 2 diabetes with advanced CKD (stage 3-4)) (from -3.7 to -1.1 mL/min/1.73m2/year).

    “Time axis averaged eGFR slope was improved from -3.7 to -1.1mL/min/1.73m2/year after adding SGLT2i.”

    Human trialtype 2 diabetes with advanced CKD (stage 3-4)64.1±30.6 monthsn = 75

    Individualized Slope Analysis: Optimizing Reno-Protective Pillars of Therapy

    ADA Scientific Sessions 2026 abstract

  2. SGLT2 inhibitors are linked with better eGFR slope in responders to SGLT2i (eGFR slope ratio below 1.0 after addition); GLP-1RA used in 55% (-7.5±9.7 to -0.8±2.8 ml/min/1.73m2/year).

    “Slopes in responders (60/75) were improved as follows, -7.5±9.7 to -0.8±2.8ml/min/1.73m2/year (P<0.01) with GLP-1RA use in 55%.”

    Humansin responders to SGLT2i (eGFR slope ratio below 1.0 after addition); GLP-1RA used in 55%n = 60

    Assessing Individual Estimated GFR Trajectory on GLP-1RA Use for Kidney Protection

    ADA Scientific Sessions 2025 abstract

  3. SGLT2 inhibitors were not clearly linked with eGFR slope in humans (months 3-12 after SGLT2i initiation) (-0.07 (-0.72 to 0.58) ml/min per 1.73 m2 per 90 days).

    “then stabilized to −0.07 (−0.72 to 0.58) ml/min per 1.73 m2 during months 3–12 postinitiation”

    Humansmonths 3-12 after SGLT2i initiationkidneymonths 3-12n = 348

    Sodium-Glucose Cotransporter-2 Inhibitor Therapy and Longitudinal Changes in Kidney Function among Veterans with Autosomal Dominant Polycystic Kidney Disease

    Clinical journal of the American Society of Nephrology : CJASN

  4. SGLT2 inhibitors decrease eGFR slope in humans.

    “Pharmacological interventions, particularly SGLT2 inhibitors, significantly slow eGFR decline and improve clinical outcomes.”

    Reviewkidney

    Estimated glomerular filtration rate slope and clinical outcomes: a narrative review

    Diabetes research and clinical practice

More on SGLT2 inhibitors

Finerenone

no changein humans1

1 study
  1. Finerenone was not clearly linked with eGFR slope in humans (Diabetic kidney disease) (From -3.29 to -2.85 mL/min/1.73 m2/year).

    “the 20 mg/day group (n = 52) remained in a stable trajectory (-3.29 to -2.85 mL/min/1.73 m2/year, p = 0.865).”

    HumansDiabetic kidney disease20 mg/daySix months after initiation versus one year before initiationn = 52

    Association of Finerenone Dose and Estimated Glomerular Filtration Rate (eGFR) Slope Changes in Patients With Diabetic Kidney Disease: A Real-World Retrospective Study

    Cureus

More on Finerenone

GLP-1 receptor agonists

upin humans1

1 study
  1. GLP-1 receptor agonists are linked with better eGFR slope in rapid decliners, combined with SGLT2i; GLP-1RA used in 85% (11/13) (-18.9±16.4 to -1.2±3.2 ml/min/1.73m2/year).

    “Slopes in rapid decliners (defined as the most rapid individual eGFR slope greater than -10.0ml/min/1.73m2/y) (13/75) were improved from -18.9±16.4 to -1.2±3.2ml/min/1.73m2/year (P<0.01)”

    Humansin rapid decliners, combined with SGLT2i; GLP-1RA used in 85% (11/13)n = 13

    Assessing Individual Estimated GFR Trajectory on GLP-1RA Use for Kidney Protection

    ADA Scientific Sessions 2025 abstract

More on GLP-1 receptor agonists

Effects

1

Heart failure

no changein humans1

1 study
  1. eGFR slope was not clearly linked with heart failure in humans (stage A HF (at elevated risk for HF)).

    “No significant association was found among individuals in stage A.”

    Humansstage A HF (at elevated risk for HF)median >6 yearsn = 1,262

    Association of Estimated GFR Slope and Heart Failure Progression in Older Adults

    American journal of kidney diseases : the official journal of the National Kidney Foundation

More on Heart failure

Associations

9

HbA1c

downin humans1

1 study
  1. HbA1c is associated with eGFR slope in humans (Type 2 diabetes; adjusted model before mutual adjustment with CGM metrics) (-0.38 [-0.65, -0.11] mL/min/1.73m2/year).

    “Higher GMI and HbA1c were associated with faster eGFR decline”

    HumansType 2 diabetes; adjusted model before mutual adjustment with CGM metricsMedian 2.3 yearsn = 1,363

    Association of continuous glucose monitoring metrics with cardiovascular and kidney outcomes in type 2 diabetes: Data from the GRADE-CGM substudy

    Journal of diabetes and its complications

More on HbA1c

Glucose management indicator

downin humans1

1 study
  1. Glucose management indicator is associated with eGFR slope in humans (Type 2 diabetes; adjusted model before mutual adjustment with HbA1c) (-0.35 [-0.63, -0.07] mL/min/1.73m2/year).

    “Higher GMI and HbA1c were associated with faster eGFR decline”

    HumansType 2 diabetes; adjusted model before mutual adjustment with HbA1cMedian 2.3 yearsn = 1,363

    Association of continuous glucose monitoring metrics with cardiovascular and kidney outcomes in type 2 diabetes: Data from the GRADE-CGM substudy

    Journal of diabetes and its complications

More on Glucose management indicator

SGLT2 inhibitors

upin humans1

1 study
  1. SGLT2 inhibitors are associated with eGFR slope in humans (B = +9.79, p = 0.016).

    “Concomitant SGLT2 inhibitor use was independently associated with greater improvement in eGFR slope”

    HumansConcomitant use with finerenone in patients with diabetic kidney disease; multivariable analysis

    Association of Finerenone Dose and Estimated Glomerular Filtration Rate (eGFR) Slope Changes in Patients With Diabetic Kidney Disease: A Real-World Retrospective Study

    Cureus

More on SGLT2 inhibitors

Finerenone

upin humans1

1 study
  1. Finerenone is associated with eGFR slope in humans (Diabetic kidney disease) (From -5.20 to +0.27 mL/min/1.73 m2/year).

    “Following finerenone initiation, the overall eGFR slope improved from -5.20 to +0.27 mL/min/1.73 m2/year (p = 0.0144).”

    HumansDiabetic kidney diseaseSix months after initiation versus one year before initiationn = 104

    Association of Finerenone Dose and Estimated Glomerular Filtration Rate (eGFR) Slope Changes in Patients With Diabetic Kidney Disease: A Real-World Retrospective Study

    Cureus

More on Finerenone

Mortality

upin humans1

1 study
  1. eGFR slope is associated with mortality in humans (steeper decline in eGFR).

    “steeper declines in eGFR are linked to increased risks of end-stage kidney disease, cardiovascular events, hospitalization, and all-cause mortality across diverse populations.”

    Reviewsteeper decline in eGFR

    Estimated glomerular filtration rate slope and clinical outcomes: a narrative review

    Diabetes research and clinical practice

End-stage renal disease

upin humans1

1 study
  1. eGFR slope is associated with end-stage renal disease in humans (steeper decline in eGFR).

    “Observational and clinical studies consistently show that steeper declines in eGFR are linked to increased risks of end-stage kidney disease, cardiovascular events, hospitalization, and all-cause mortality”

    Reviewsteeper decline in eGFR

    Estimated glomerular filtration rate slope and clinical outcomes: a narrative review

    Diabetes research and clinical practice

More on End-stage renal disease

GrimAge2logA1c

downin humans1

1 study
  1. GrimAge2logA1c predicts eGFR slope in type 2 diabetes (β = -0.113, p = 4.77 × 10−3).

    “GrimAge2logA1c was both highest in SIRD-RII and the only clock associated with kidney function decline (eGFR slope, β [SE] = -0.113 [0.040], p = 4.77 × 10−3).”

    Humansin type 2 diabetes7.3 yearsn = 607

    DNA aging patterns differ across type 2 diabetes groups

    GeroScience

More on GrimAge2logA1c

FGF23

downin humans1

1 study
  1. FGF23 is associated with eGFR slope in humans (unadjusted/baseline correlation).

    “Higher baseline ePTFp and serum FGF23 were inversely correlated with eGFR slope.”

    Humansunadjusted/baseline correlation5 yearsn = 308

    Renal tubular calcium phosphate microcrystallopathy and age-related kidney function decline: The Aging Kidney Study

    Clinical kidney journal

More on FGF23

Estimated proximal tubular fluid phosphate concentration

downin humans1

1 study
  1. Estimated proximal tubular fluid phosphate concentration is associated with eGFR slope in adults with and without CKD.

    “elevated ePTFp remained independently associated with faster eGFR decline”

    Humansin adults with and without CKD5 yearsn = 308

    Renal tubular calcium phosphate microcrystallopathy and age-related kidney function decline: The Aging Kidney Study

    Clinical kidney journal

More on Estimated proximal tubular fluid phosphate concentration

Latest

Dec 2025: 4Jan 2026: 4Feb 2026: 2Mar 2026: 2Apr 2026: 1May 2026: 0Jun 2026: 4Jul 2026: 3Aug 2026: 2Sep 2026: 2Oct 2026: 7Nov 2026: 536 papers in 12 months
GeroScience

DNA aging patterns differ across type 2 diabetes groups

An observational study of 607 multi-ethnic Asians linked one DNA-based aging measure to kidney function decline over a median 7.3 years.An observational study of 607 multi-ethnic Asians linked one DNA-based aging measure to kidney function decline over a median 7.3 years.

Cohort · 607 peopleType 2 diabetes

See all 52 papers on eGFR slope